BR112022018677A2 - Receptor de antígeno quimérico combinado que alveja cd19 e cd20 e aplicação do mesmo - Google Patents
Receptor de antígeno quimérico combinado que alveja cd19 e cd20 e aplicação do mesmoInfo
- Publication number
- BR112022018677A2 BR112022018677A2 BR112022018677A BR112022018677A BR112022018677A2 BR 112022018677 A2 BR112022018677 A2 BR 112022018677A2 BR 112022018677 A BR112022018677 A BR 112022018677A BR 112022018677 A BR112022018677 A BR 112022018677A BR 112022018677 A2 BR112022018677 A2 BR 112022018677A2
- Authority
- BR
- Brazil
- Prior art keywords
- targets
- antigen receptor
- chimeric antigen
- present
- application
- Prior art date
Links
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 title abstract 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title abstract 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 title abstract 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title abstract 7
- 208000037914 B-cell disorder Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
RECEPTOR DE ANTÍGENO QUIMÉRICO COMBINADO QUE ALVEJA CD19 E CD20 E APLICAÇÃO DO MESMO. A presente invenção fornece um receptor de antígeno quimérico combinado que alveja CD19 e CD20 e aplicação do mesmo. Especificamente, a presente invenção fornece um receptor de antígeno quimérico combinado que alveja CD19 e CD20, que compreende um scFv que alveja CD19 e um scFv que alveja CD20, uma região de dobradiça, uma região transmembranas e um domínio de sinalização intracelular. A presente invenção fornece uma molécula de ácido nucleico que codifica o receptor de antígeno quimérico e um vetor de expressão correspondente, uma célula T de CAR, e aplicações da mesma. Os resultados experimentais mostram que o receptor de antígeno quimérico fornecido pela presente invenção mostra capacidade de extermínio extremamente alta contra células tumorais. O receptor de antígeno quimérico da presente invenção alveja células positivadas para CD19 e/ou CD20 e pode ser usado para tratar linfoma, leucemia e outras doenças de célula B positivadas para CD19 e/ou CD20.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010188038.1A CN113402612A (zh) | 2020-03-17 | 2020-03-17 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
US16/877,069 US11207349B2 (en) | 2020-03-17 | 2020-05-18 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof |
PCT/CN2020/109645 WO2021184673A1 (en) | 2020-03-17 | 2020-08-17 | Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof |
US202163154032P | 2021-02-26 | 2021-02-26 | |
PCT/US2021/022779 WO2021188681A1 (en) | 2020-03-17 | 2021-03-17 | Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022018677A2 true BR112022018677A2 (pt) | 2023-02-23 |
Family
ID=77677447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022018677A BR112022018677A2 (pt) | 2020-03-17 | 2021-03-17 | Receptor de antígeno quimérico combinado que alveja cd19 e cd20 e aplicação do mesmo |
Country Status (18)
Country | Link |
---|---|
US (5) | US11207349B2 (pt) |
EP (1) | EP3989986A4 (pt) |
JP (3) | JP2023518134A (pt) |
KR (2) | KR20230053705A (pt) |
CN (2) | CN113402612A (pt) |
AU (2) | AU2021238330B2 (pt) |
BR (1) | BR112022018677A2 (pt) |
CA (2) | CA3169235A1 (pt) |
CL (1) | CL2022002522A1 (pt) |
CO (1) | CO2022014259A2 (pt) |
CR (1) | CR20220507A (pt) |
DO (1) | DOP2022000195A (pt) |
EC (1) | ECSP22079948A (pt) |
IL (1) | IL296473A (pt) |
MX (1) | MX2022011554A (pt) |
NZ (1) | NZ793365A (pt) |
PE (1) | PE20231643A1 (pt) |
WO (2) | WO2021184673A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
WO2023208157A1 (zh) * | 2022-04-29 | 2023-11-02 | 上海先博生物科技有限公司 | 靶向cd19的嵌合抗原受体及其应用 |
CN114990069B (zh) * | 2022-05-17 | 2023-09-22 | 郑州大学第一附属医院 | 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用 |
US20240075142A1 (en) * | 2022-08-26 | 2024-03-07 | Lentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy |
CN116514992B (zh) * | 2022-11-07 | 2024-05-24 | 武汉波睿达生物科技有限公司 | 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗cd19抗体 |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
JP5727786B2 (ja) | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス,インコーポレーテッド | Cd19結合性物質およびその使用 |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013176916A1 (en) | 2012-05-25 | 2013-11-28 | Roman Galetto | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
JP6450690B2 (ja) | 2013-02-15 | 2019-01-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | キメラ抗原受容体及びその使用方法 |
US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
SG10201804439PA (en) * | 2013-12-20 | 2018-06-28 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
GB201407852D0 (en) * | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
AU2015270912B9 (en) | 2014-06-02 | 2021-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting CD-19 |
TWI805109B (zh) * | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
JP7057669B2 (ja) | 2014-10-20 | 2022-04-20 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法において投薬するための方法および組成物 |
CA3008162A1 (en) * | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
KR102663073B1 (ko) | 2015-01-08 | 2024-05-07 | 젠맵 에이/에스 | Cd3 및 cd20에 대항한 이중특이적 항체 |
US11248058B2 (en) | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
EP3283113A4 (en) * | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
WO2016176651A2 (en) * | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
WO2016179319A1 (en) | 2015-05-04 | 2016-11-10 | Cellerant Therapeutics, Inc. | Chimeric antigen receptors with ctla4 signal transduction domains |
US10639329B2 (en) | 2015-06-12 | 2020-05-05 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
US10493139B2 (en) * | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
JP6751493B2 (ja) | 2015-08-05 | 2020-09-09 | セルレブメド インコーポレーテッド | キメラ抗原受容体及びキメラ抗原受容体が発現されたt細胞 |
AU2016306209B2 (en) | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
EP3340995A4 (en) | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | METHODS AND COMPOSITIONS FOR CELLS EXPRESSING A CHIMERIC INTRACELLULAR SIGNALING MOLECULE |
AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
EP3436037A4 (en) * | 2016-03-31 | 2019-12-04 | University of Southern California | HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE-BASED REPORTER TEST FOR ANTIGEN DETECTION |
KR102584280B1 (ko) | 2016-04-01 | 2023-10-04 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
CN117866991A (zh) * | 2016-10-07 | 2024-04-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
CN108276493B (zh) | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
BR112019017401A2 (pt) * | 2017-02-22 | 2020-04-14 | Aleta Biotherapeutics Inc | composições e métodos para transdução tumoral |
JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
US11434290B2 (en) | 2017-06-08 | 2022-09-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced NFκB signaling |
CN111183156A (zh) | 2017-07-31 | 2020-05-19 | 莱蒂恩技术公司 | 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法 |
CN109423495A (zh) | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
US10501539B2 (en) | 2017-09-15 | 2019-12-10 | Lentigen Technology Inc. | Compositions and methods for treating cancer with anti-CD19 immunotherapy |
TW201922256A (zh) * | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
US20220218745A1 (en) | 2017-12-22 | 2022-07-14 | 2Seventy Bio, Inc. | Multivalent chimeric antigen receptor |
CN108315305B (zh) | 2017-12-26 | 2020-11-06 | 沣潮医药科技(上海)有限公司 | 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用 |
CN108017717B (zh) | 2018-01-24 | 2019-08-16 | 首都医科大学宣武医院 | 一种用于体外高效定向扩增的嵌合抗原受体及其应用 |
WO2019154313A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
KR20210033941A (ko) | 2018-04-28 | 2021-03-29 | 이뮤노테크 바이오팜 씨오., 엘티디. | 개선된 t-세포 요법 |
CN110526983B (zh) | 2018-05-24 | 2022-02-11 | 北京马力喏生物科技有限公司 | 改良型抗cd19 car-t细胞 |
CN110606893B (zh) | 2018-06-15 | 2022-11-15 | 北昊干细胞与再生医学研究院有限公司 | 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法 |
WO2020010235A1 (en) | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
AU2019354391A1 (en) | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors |
CN109536455B (zh) | 2018-12-11 | 2020-02-21 | 武汉波睿达生物科技有限公司 | 一种car-nk细胞及其制备方法和应用 |
WO2020123691A2 (en) * | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc | Chimeric antigen and t cell receptors and methods of use |
CN109575143B (zh) | 2018-12-29 | 2022-06-17 | 博生吉医药科技(苏州)有限公司 | 双特异性cd20-cd19-car及其应用 |
CN113330038A (zh) | 2019-01-22 | 2021-08-31 | 亘喜生物科技(上海)有限公司 | Cd20组合靶向的工程化免疫细胞 |
CN112390891B (zh) | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
CN112608387B (zh) | 2020-12-21 | 2023-05-05 | 汤朝阳 | Cd19和cd20双靶点嵌合抗原受体及其应用 |
-
2020
- 2020-03-17 CN CN202010188038.1A patent/CN113402612A/zh active Pending
- 2020-05-18 US US16/877,069 patent/US11207349B2/en active Active
- 2020-08-17 WO PCT/CN2020/109645 patent/WO2021184673A1/en active Application Filing
- 2020-08-17 JP JP2022506548A patent/JP2023518134A/ja active Pending
- 2020-08-17 CA CA3169235A patent/CA3169235A1/en active Pending
-
2021
- 2021-03-17 EP EP21772208.1A patent/EP3989986A4/en active Pending
- 2021-03-17 AU AU2021238330A patent/AU2021238330B2/en active Active
- 2021-03-17 CA CA3169239A patent/CA3169239A1/en active Pending
- 2021-03-17 BR BR112022018677A patent/BR112022018677A2/pt unknown
- 2021-03-17 CR CR20220507A patent/CR20220507A/es unknown
- 2021-03-17 KR KR1020237011866A patent/KR20230053705A/ko active Application Filing
- 2021-03-17 MX MX2022011554A patent/MX2022011554A/es unknown
- 2021-03-17 IL IL296473A patent/IL296473A/en unknown
- 2021-03-17 WO PCT/US2021/022779 patent/WO2021188681A1/en active Application Filing
- 2021-03-17 JP JP2022506726A patent/JP7212222B2/ja active Active
- 2021-03-17 KR KR1020227035401A patent/KR102520550B1/ko active IP Right Grant
- 2021-03-17 NZ NZ793365A patent/NZ793365A/en unknown
- 2021-03-17 CN CN202180035520.4A patent/CN115955974A/zh active Pending
- 2021-03-17 PE PE2022002042A patent/PE20231643A1/es unknown
- 2021-09-15 US US17/475,766 patent/US11439665B2/en active Active
-
2022
- 2022-04-15 US US17/721,647 patent/US20220249568A1/en active Pending
- 2022-05-23 US US17/750,658 patent/US11633430B2/en active Active
- 2022-09-15 CL CL2022002522A patent/CL2022002522A1/es unknown
- 2022-09-20 DO DO2022000195A patent/DOP2022000195A/es unknown
- 2022-10-05 CO CONC2022/0014259A patent/CO2022014259A2/es unknown
- 2022-10-13 EC ECSENADI202279948A patent/ECSP22079948A/es unknown
- 2022-12-19 JP JP2022202035A patent/JP2023027314A/ja active Pending
-
2023
- 2023-01-19 AU AU2023200268A patent/AU2023200268A1/en active Pending
- 2023-03-14 US US18/183,681 patent/US20240139243A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022018677A2 (pt) | Receptor de antígeno quimérico combinado que alveja cd19 e cd20 e aplicação do mesmo | |
CO2019007868A2 (es) | Anticuerpos agonistas anti-icos y sus usos | |
AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
JOP20210076A1 (ar) | تركيبات أجسام مضادة ثنائية الاختصاص لربط خلايا تائية | |
MX2020008795A (es) | Anti cuerpos anti tigit y usos de los mismos. | |
CO2017005845A2 (es) | Anticuerpos monoclonales aislados contra cd73 | |
MX2023003418A (es) | Moleculas multiespecificas de union a antigenos y usos de estas. | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
CR20190440A (es) | Receptores de unión a antígeno mejorados | |
CL2019001459A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1. | |
WO2018234793A3 (en) | Antibodies | |
CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
PE20181013A1 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
BR112017003582A2 (pt) | anticorpos, composições e usos | |
BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
BRPI0610796B8 (pt) | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo | |
BR112017019617A2 (pt) | Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada | |
Rafei et al. | Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia | |
Mishra et al. | Preclinical development of CD126 CAR-T cells with broad antitumor activity | |
CO2020009034A2 (es) | Constructo de anticuerpo biespecífico dirigido a muc17 y cd3 | |
Mladenov et al. | The Fc‐alpha receptor is a new target antigen for immunotherapy of myeloid leukemia | |
Seitz et al. | Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting | |
MX2021002500A (es) | Anticuerpos y secuencias de nucleotidos novedosos, y sus usos. | |
CR20230229A (es) | Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada | |
Li et al. | Engineering clinically-approved drug gated CAR circuits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: CELLULAR BIOMEDICINE GROUP, INC. (US) |